FutureWiseResearch: Global Market Research Reports, USA, UK

Overview

Immunotherapy Drugs Market Overview:

According to FutureWise analysis the market for Immunotherapy Drugs is expected to reach US$ 408.4 billion by 2031 at a CAGR of 11%.

The immune system is boosted or suppressed by immunotherapy drugs. The main purpose of these medications is to treat cancer. They stimulate the immune system and produce antibodies by stimulating the immune response. The antigen-specific antibodies kill cancerous cells or tumors. Due to the increase in cancer incidence, it is expected that the global market for immunotherapy drugs will grow significantly during the forecast period. Global immunotherapy market growth is driven by the increasing use of targeted therapies, an increase in patient life expectancy, and a high prevalence of lifestyle-related diseases. The market is also driven by rapid approvals of drugs and a reduction in the occurrence of diseases. Due to the high cost of immunotherapy treatments and the longer product development cycles, the market is hindered. In contrast, the use of immunotherapy in place of chemotherapy and as the first drug in the treatment of cancer will provide opportunities for market growth in the near term.

Immunotherapy boosts the immune system of the body to combat cancer cells. It uses components that are made in-house or in vitro. Different Immunotherapies work on different mechanisms. Some immunotherapy treatments can stop cancer cell growth. Some therapies help the immune system eliminate cancer cells or prevent cancer from spreading. Cancer treatments that use immunotherapy can be combined with other treatments or used alone.

The increasing occurrences of targeted diseases, rising insistence for biosimilars and monoclinal antibodies, rising acceptance of immunotherapy drugs over traditional drugs are some of the key factors responsible for the immunotherapy drugs market growth. Conversely, side-effects of these drugs, issues related to the timeline and complexities in manufacturing and a high rate of attrition in the product development cycle shall impede the proliferation of the market.

Major players included in the Immunotherapy Drugs Market:

F. Hoffmann-La Roche Ltd.
Pfizer Inc.
Merck and Co
Novartis International AG
Johnson and Johnson
Sanofi
GlaxoSmithKline Plc
Amgen Inc.
Abbvie Inc.
Boehringer Ingelheim
AstraZeneca
Immatics Biotechnologies
Biontech SE
Genmab
Gilead Sciences
NBE Therapeutics
Teva Pharmaceuticals
Bayer
Bristol-Myers Squibb
Eli Lilly And Company
Incyte Corporation

(Note: The list of the major players will be updated with the latest market scenario and trends)

Immunotherapy Drugs Market Segmentation:

By Type

Checkpoint Inhibitors
Adult Vaccines
Interleukins
Monoclonal Antibodies
Interferons
Alpha And Beta
Others

By Therapy Area

Cancer
Infectious Diseases
Autoimmune and Inflammatory Diseases

By End User

Clinics
Hospitals
Others

By Region

North America
Europe
Asia-Pacific
Latin America
Middle East and Africa

The North America region is anticipated to dominate the market owing to rising incidences of autoimmune diseases and cancer, rising insistence for safe therapies, growing FDA approvals and favourable reimbursement scenarios.

The market is categorised into type, therapy area, end user and region. The type segment is fragmented into check point inhibitors, monoclonal antibodies, interleukins and interferons. The monoclonal antibodies segment held the largest immunotherapy drugs market share owing to fewer side effects and high specificity, rising emphasis on personalised medicines, increased prevalence of targeted diseases and growing initiatives by key market players. The therapy area segment is classified into cancer, infectious diseases and autoimmune and inflammatory diseases. Cancer segment led the market in 2019 and this can be credited to rising incidence of cancer, favourable reimbursement scenarios for oncology. The end user segment is diversified into clinics, hospitals and other end users. The hospital segment is predicted to dominate the market owing to the increased hospital expenditure for immunotherapies.

Competitive Landscape:

Tier 1 players- established companies in the market with a major market share
Tier 2 players
Emerging players which are growing rapidly
New Entrants

FutureWise Key Takeaways:

Growth prospects
SWOT analysis
Key trends
Key data-points affecting market growth

Objectives of the Study:

To provide with an exhaustive analysis on the Immunotherapy Drugs Market By Type, By Therapy Area, By End-User and By Region.
To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
To evaluate and forecast micro-markets and the overall market
To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
To record and evaluate competitive landscape mapping- Type launches, technological advancements, mergers and expansions

Flexible Delivery Model:

We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
The customization Mobility Care offered are free of charge with purchase of any license of the report
You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

1. Market Introduction
- 1. Objectives of the Study
  2. Market Definition
  3. Market Scope
  3.1. Years Considered for the Study
  3.2. Market Covered
  4. Currency
  5. Limitations
  6. Stakeholders
2. Research Methodology
- 1. Research Data
  1.1. Secondary Data
  1.1.1. Key Data from Secondary Sources
  1.2. Primary Data
  1.2.1. Key Data from Primary Sources
  2. Market Size Estimation
  3. Market Breakdown and Data Triangulation
  4. Assumptions for the Study
3. Executive Summary
- 1. Market Outlook
  2. Segment Outlook
  3. Competitive Insights
4. Immunotherapy Drugs Market Variables, Trends and Scope
- 1. Market Lineage Outlook
  2. Penetration and Growth Prospect Mapping
  3. Industry Value Chain Analysis
  4. Cost Analysis Breakdown
  5. Technology Overview
  6. Regulatory Framework
  6.1. Reimbursement Framework
  6.2. Standards and Compliances
5. Market Overview
- 1. Market Dynamics
  1.1. Market Driver Analysis
  1.1.1. Increasing focus of Immunotherapy Drugs Market Companies on Brand Protection
  1.1.2. Untapped Opportunities in Emerging Regions
  1.2. Market Restraint Analysis
  1.2.1. High Cost Associated with Implementation of Predictive Analysis
  1.3. Industry Challenges
  1.3.1. Presence of Ambiguous Regulatory Framework
6. Immunotherapy Drugs Market Analysis Tools
- 1. Industry Analysis - Porter’s
  1.1. Supplier Power
  1.2. Buyer Power
  1.3. Substitution Threat
  1.4. Threat from New Entrants
  1.5. Competitive Rivalry
  2. Pestel Analysis
  2.1. Political Landscape
  2.2. Environmental Landscape
  2.3. Social Landscape
  2.4. Technology Landscape
  2.5. Legal Landscape
  3. Major Deals And Strategic Alliances Analysis
  3.1. Joint Ventures
  3.2. Mergers and Acquisitions
  3.3. Licensing and Partnership
  3.4. Technology Collaborations
  3.5. Strategic Divestments
  4. Market Entry Strategies
  5. Case Studies
7. Immunotherapy Drugs Market, By Type Historical Analysis and Forecast 2023-2031 (USD Million)
- 1. Checkpoint Inhibitors
  2. Adult Vaccines
  3. Interleukins
  4. Monoclonal Antibodies
  5. Interferons
  6. Alpha And Beta
  7. Others
8. Immunotherapy Drugs Market, By Therapy Area Historical Analysis and Forecast 2023-2031 (USD Million)
- 1. Cancer
  2. Infectious Diseases
  3. Autoimmune and Inflammatory Diseases
9. Immunotherapy Drugs Market, By End User Historical Analysis and Forecast 2023-2031 (USD Million)
- 1. Hospital
  2. Clinics
  3. Others
10. North America Immunotherapy Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
- 1. Introduction
  2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
  2.1. U.S.A
  2.2. Canada
  2.3. Mexico
  3. Market Size (USD Million) Forecast for North America 2023-2031
11. Latin America Immunotherapy Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
- 1. Introduction
  2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
  2.1. Brazil
  2.2. Venezuela
  2.3. Argentina
  2.4. Rest of Latin America
  3. Market Size (USD Million) Forecast for Latin America 2023-2031
12. Europe Immunotherapy Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
- 1. Introduction
  2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
  2.1. Germany
  2.2. U.K
  2.3. France
  2.4. Italy
  2.5. Spain
  2.6. Russia
  2.7. Poland
  2.8. Rest of Europe
  3. Market Size (USD Million) Forecast for Europe 2023-2031
13. Asia Pacific Immunotherapy Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
- 1. Introduction
  2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
  2.1. Japan
  2.2. China
  2.3. India
  2.4. Australia and New Zealand
  2.5. ASEAN
  2.6. Rest of Asia Pacific
  3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031
14. Middle East and Africa Immunotherapy Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
- 1. Introduction
  2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
  2.1. GCC
  2.2. Israel
  2.3. South Africa
  2.4. Rest of MEA
  3. Market Size (USD Million) Forecast for MEA 2023-2031
15. Market Share Analysis and Competitive Landscape
- 1. Global Landscape - Key Players, Revenue and Presence
  2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
  3. Global Emerging Companies
  4. North America - Market Share Analysis and Key Regional Players
  5. Europe - Market Share Analysis and Key Regional Players
  6. Asia Pacific - Market Share Analysis and Key Regional Players
  7. Global Key Player - Growth Matrix
16. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
- 1. F. Hoffmann-La Roche Ltd.
  1.1. Company Overview
  1.2. Product Portfolio
  1.3. SWOT Analysis
  1.4. Financial Overview
  1.5. Strategic Overview
  2. Pfizer Inc.
  2.1. Company Overview
  2.2. Product Portfolio
  2.3. SWOT Analysis
  2.4. Financial Overview
  2.5. Strategic Overview
  3. Merck and Co
  3.1. Company Overview
  3.2. Product Portfolio
  3.3. SWOT Analysis
  3.4. Financial Overview
  3.5. Strategic Overview
  4. Novartis International AG
  4.1. Company Overview
  4.2. Product Portfolio
  4.3. SWOT Analysis
  4.4. Financial Overview
  4.5. Strategic Overview
  5. Johnson and Johnson
  5.1. Company Overview
  5.2. Product Portfolio
  5.3. SWOT Analysis
  5.4. Financial Overview
  5.5. Strategic Overview
  6. Sanofi
  6.1. Company Overview
  6.2. Product Portfolio
  6.3. SWOT Analysis
  6.4. Financial Overview
  6.5. Strategic Overview
  7. GlaxoSmithKline Plc
  7.1. Company Overview
  7.2. Product Portfolio
  7.3. SWOT Analysis
  7.4. Financial Overview
  7.5. Strategic Overview
  8. Amgen Inc.
  8.1. Company Overview
  8.2. Product Portfolio
  8.3. SWOT Analysis
  8.4. Financial Overview
  8.5. Strategic Overview
  9. Abbvie Inc.
  9.1. Company Overview
  9.2. Product Portfolio
  9.3. SWOT Analysis
  9.4. Financial Overview
  9.5. Strategic Overview
  10. Boehringer Ingelheim
  10.1. Company Overview
  10.2. Product Portfolio
  10.3. SWOT Analysis
  10.4. Financial Overview
  10.5. Strategic Overview
  11. AstraZeneca
  11.1. Company Overview
  11.2. Product Portfolio
  11.3. SWOT Analysis
  11.4. Financial Overview
  11.5. Strategic Overview
  12. Immatics Biotechnologies
  12.1. Company Overview
  12.2. Product Portfolio
  12.3. SWOT Analysis
  12.4. Financial Overview
  12.5. Strategic Overview
  13. Biontech SE
  13.1. Company Overview
  13.2. Product Portfolio
  13.3. SWOT Analysis
  13.4. Financial Overview
  13.5. Strategic Overview
  14. Genmab
  14.1. Company Overview
  14.2. Product Portfolio
  14.3. SWOT Analysis
  14.4. Financial Overview
  14.5. Strategic Overview
  15. Gilead Sciences
  15.1. Company Overview
  15.2. Product Portfolio
  15.3. SWOT Analysis
  15.4. Financial Overview
  15.5. Strategic Overview
  16. NBE Therapeutics
  16.1. Company Overview
  16.2. Product Portfolio
  16.3. SWOT Analysis
  16.4. Financial Overview
  16.5. Strategic Overview
  17. Teva Pharmaceuticals
  17.1. Company Overview
  17.2. Product Portfolio
  17.3. SWOT Analysis
  17.4. Financial Overview
  17.5. Strategic Overview
  18. Bayer
  18.1. Company Overview
  18.2. Product Portfolio
  18.3. SWOT Analysis
  18.4. Financial Overview
  18.5. Strategic Overview
  19. Bristol-Myers Squibb
  19.1. Company Overview
  19.2. Product Portfolio
  19.3. SWOT Analysis
  19.4. Financial Overview
  19.5. Strategic Overview
  20. Eli Lilly And Company
  20.1. Company Overview
  20.2. Product Portfolio
  20.3. SWOT Analysis
  20.4. Financial Overview
  20.5. Strategic Overview
  21. Incyte Corporation
  21.1. Company Overview
  21.2. Product Portfolio
  21.3. SWOT Analysis
  21.4. Financial Overview
  21.5. Strategic Overview
17. Pre and Post COVID-19 Impact
- 1. Positive influence on the healthcare industry
  2. The financial disruption of the manufacturing sector
  3. Impact of COVID-19 on emerging companies
  4. Significant mandates in the regulations initiated by healthcare administrations
  5. The overall economic slowdown of the developing and developed nations
18. FutureWise SME Key Takeaway Points for Client

Data Pack license: Data Pack license: $1250

Single user license: Single user license: $2850

Multi user license: Multi user license: $3850

Corporate license: Corporate license: $5000

Ask for Discount

Buy Now

Customize This Report

Partner

Report Overview

Table of Contents

List of Tables

List of figures

Overview

Table of Contents

Report Overview

Table of Contents

List of Tables

List of figures

Need Assistance

What you get

What's included

Our Clients